X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Sun Pharma with Sterling Biotech - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

SUN PHARMA vs STERLING BIOTECH - Comparison Results

SUN PHARMA    Change

Sun Pharma holds 3.7% share of the domestic pharma market (as per the latest ORG IMS MAT data) and has a strong presence in the lifestyle therapeutic segments. The company started focusing on the exports market in FY02, when it increased its stake to... More

STERLING BIOTECH 
   Change

Sterling Biotech primarily produces and distributes pharmaceutical grade gelatine globally. The company currently has a 7.5% share of the global market for pharmaceutical and nutraceutical gelatines. It has more than 70% market share in India. Sterli... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    SUN PHARMA STERLING BIOTECH SUN PHARMA/
STERLING BIOTECH
 
P/E (TTM) x 34.2 -0.4 - View Chart
P/BV x 2.7 0.0 18,608.2% View Chart
Dividend Yield % 0.5 0.0 -  

Financials

 SUN PHARMA   STERLING BIOTECH
EQUITY SHARE DATA
    SUN PHARMA
Mar-18
STERLING BIOTECH
Dec-13
SUN PHARMA/
STERLING BIOTECH
5-Yr Chart
Click to enlarge
High Rs70111 6,671.4%   
Low Rs4333 12,741.2%   
Sales per share (Unadj.) Rs110.426.8 411.9%  
Earnings per share (Unadj.) Rs11.0-15.0 -73.4%  
Cash flow per share (Unadj.) Rs17.2-5.5 -315.4%  
Dividends per share (Unadj.) Rs2.000-  
Dividend yield (eoy) %0.40-  
Book value per share (Unadj.) Rs158.854.9 289.4%  
Shares outstanding (eoy) m2,399.26267.87 895.7%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x5.10.3 1,980.3%   
Avg P/E ratio x51.6-0.5 -11,112.7%  
P/CF ratio (eoy) x32.9-1.3 -2,586.1%  
Price / Book Value ratio x3.60.1 2,818.8%  
Dividend payout %18.20-   
Avg Mkt Cap Rs m1,360,0211,862 73,052.7%   
No. of employees `00017.81.4 1,313.8%   
Total wages/salary Rs m53,671547 9,815.4%   
Avg. sales/employee Rs Th14,890.95,303.3 280.8%   
Avg. wages/employee Rs Th3,017.1403.8 747.1%   
Avg. net profit/employee Rs Th1,480.6-2,959.0 -50.0%   
INCOME DATA
Net Sales Rs m264,8957,181 3,689.0%  
Other income Rs m8,38843 19,689.2%   
Total revenues Rs m273,2827,223 3,783.3%   
Gross profit Rs m56,081947 5,922.6%  
Depreciation Rs m14,9982,543 589.7%   
Interest Rs m5,1764,377 118.2%   
Profit before tax Rs m44,295-5,931 -746.9%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m-9,5050-   
Tax Rs m8,452-1,924 -439.2%   
Profit after tax Rs m26,338-4,007 -657.4%  
Gross profit margin %21.213.2 160.5%  
Effective tax rate %19.132.4 58.8%   
Net profit margin %9.9-55.8 -17.8%  
BALANCE SHEET DATA
Current assets Rs m316,35914,335 2,206.9%   
Current liabilities Rs m198,64349,809 398.8%   
Net working cap to sales %44.4-494.0 -9.0%  
Current ratio x1.60.3 553.4%  
Inventory Days Days95403 23.5%  
Debtors Days Days108171 63.1%  
Net fixed assets Rs m213,17855,432 384.6%   
Share capital Rs m2,399268 895.6%   
"Free" reserves Rs m378,60613,935 2,716.9%   
Net worth Rs m381,00614,701 2,591.7%   
Long term debt Rs m17,7219,478 187.0%   
Total assets Rs m643,02873,988 869.1%  
Interest coverage x9.6-0.4 -2,692.8%   
Debt to equity ratio x00.6 7.2%  
Sales to assets ratio x0.40.1 424.5%   
Return on assets %4.90.5 978.4%  
Return on equity %6.9-27.3 -25.4%  
Return on capital %10.0-6.4 -156.0%  
Exports to sales %025.9 0.0%   
Imports to sales %00.2 0.0%   
Exports (fob) Rs mNA1,860 0.0%   
Imports (cif) Rs mNA12 0.0%   
Fx inflow Rs m40,8161,860 2,194.7%   
Fx outflow Rs m30,14325 121,106.5%   
Net fx Rs m10,6731,835 581.7%   
CASH FLOW
From Operations Rs m39,0721,719 2,273.3%  
From Investments Rs m-33,708-3,148 1,070.7%  
From Financial Activity Rs m-15,3931,426 -1,079.4%  
Net Cashflow Rs m-7,359-3 216,444.1%  

Share Holding

Indian Promoters % 63.7 33.9 187.9%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 5.1 0.0 -  
FIIs % 23.0 9.9 232.3%  
ADR/GDR % 0.0 16.9 -  
Free float % 8.3 39.3 21.1%  
Shareholders   133,026 21,482 619.2%  
Pledged promoter(s) holding % 0.5 55.9 0.9%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare SUN PHARMA With:   NATCO PHARMA  PANACEA BIOTECH  WOCKHARDT LTD.  TORRENT PHARMA  PLETHICO PHARMA  

Compare SUN PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

From Urjit Patel to Shaktikanta Das; What Lies Ahead?(Podcast)

The week gone by saw Sensex plunge from 700 points to rise by over 600 points. With a volatile and eventful week, it was a challenge keeping up with the news every day.

Related Views on News

SUN PHARMA Announces Quarterly Results (2QFY19); Net Profit Down 110.7% (Quarterly Result Update)

Nov 14, 2018 | Updated on Nov 14, 2018

For the quarter ended September 2018, SUN PHARMA has posted a net profit of Rs 1 bn (down 110.7% YoY). Sales on the other hand came in at Rs 69 bn (up 4.3% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.

SUN PHARMA 2017-18 Annual Report Analysis (Annual Result Update)

Sep 19, 2018 | Updated on Sep 19, 2018

Here's an analysis of the annual report of SUN PHARMA for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of SUN PHARMA. Also includes updates on the valuation of SUN PHARMA.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

4 Rebound Stocks to Profit from the Current Small Cap Crash(Profit Hunter)

Dec 3, 2018

Indian small cap space is offering a discount season. Make sure you do not get too late to scoop up the bargains.

It's Almost the Perfect Time to Buy This Safe Stock(The 5 Minute Wrapup)

Dec 6, 2018

My latest StockSelect recommendation ticks all the boxes of a great safe stock.

Looking For Higher Interest Rates on Bank FDs? Read This!(Outside View)

Dec 5, 2018

Credit disbursement to the productive sectors of the economy such as infrastructure, engineering, food processing, textiles, and chemicals, among others is rising.

Are Foreign Investors Heading Back to the Indian Stock Markets?(Chart Of The Day)

Dec 3, 2018

After months of heavy FII selling, November witnessed a return on foreign money into Indian equities...

DSP Mutual Fund's Sale of DHFL Bonds: Here's What You Need to Know(Outside View)

Dec 5, 2018

PersonalFN explains the probable reason as to why the capital market regulator has initiated DSP Mutual Fund's bond sale that caused DHFL stock to crash.

More

Small Investments
BIG Returns

Zero To Millions Guide 2019
Get our special report, Zero To Millions
(2019 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

SUN PHARMA SHARE PRICE


Dec 14, 2018 (Close)

TRACK SUN PHARMA

  • Track your investment in SUN PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

COMPARE SUN PHARMA WITH

MARKET STATS